IPD’s Saudi Arabian subscription brings local expertise to this unique market, offering:

​

• Loss-of-exclusivity insights based on
  detailed analysis of Saudi Arabian
  and GCC patents
   

• Easy-to-use Saudi Arabian drug launch
  tracking schedules including pending and recent
  brand approvals, lunched biosimilars,
  and pending and recent generic approvals
   

• ƒPersonalized consults with Saudi Arabian intellectual property analysts 
   

• ƒComplete drug information with locally reviewed Saudi Arabian indications
   

• Saudi Arabian API (DMF) information
   

• Visibility into patent information and/or brand and generic approvals in other impactful
  MENA countries, including Egypt, Jordan, Morocco, and United Arab Emirates (UAE)